Skip to main content
Premium Trial:

Request an Annual Quote

Checkmarks in Both the 'Pro' and 'Con' Columns

The BBC speaks with 23andMe's Linda Avey and Anne Wojcicki about their company and their motivation. "The reason we started this company is that we really dramatically wanted to change healthcare," Wojcicki tells the BBC. Avey adds that they think that if people know their genetic information, they will take better care of themselves. The BBC also mentions that FDA is "warming to personal gene services," though the public still has some concerns.

The ETC Group is issuing a series of reports on "impact and implications of human genomics." Its first report, found here, focuses on direct-to-consumer testing and personalized medicine, concluding that "what's really happening is that consumers are being recruited to be research subjects. … They are paying out of their own pockets for the privilege, armed with little knowledge and even less control over the final use of their samples."

 

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.